Drug Topics
APRIL 28, 2025
Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discusses litigious, market-based, and legislative reform for pharmacy benefit managers.
STAT
APRIL 29, 2025
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators to be in shortage, so compounding pharmacies and the telehealth companies they work with must stop offering copies of the treatments.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
APRIL 29, 2025
U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.
PhRMA
MAY 1, 2025
Patients in the U.S. will soon be left with fewer new, affordable and convenient treatments, if Congress fails to fix a harmful provision in the Inflation Reduction Act (IRA) referred to as the “pill penalty.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
APRIL 29, 2025
Glucagon-like peptide-1 medications are the fastest-growing class of medication and will continue to be prevalent as more indications, such as sleep apnea, are added.
STAT
MAY 1, 2025
The era of “tranq” may be ending. But tranq, as the powerful veterinary tranquilizer xylazine is known in the illicit drug supply, is being replaced at least in part by a dangerous new sedative: medetomidine. In the past year, the anesthetic has become an increasingly common element in the drug supply, with cities and states including Philadelphia, Pittsburgh, Chicago, and San Francisco reporting cases of medetomidine-involved overdoses.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
PhRMA
MAY 1, 2025
The 340B hospital markup program continues to skyrocket every year. Yet there is little to no evidence that this immense growth is benefiting the uninsured and low-income patients that the program was designed to serve. If the money isn’t going to help patients, where is it going?
Drug Topics
MAY 1, 2025
The Inflation Reduction Act's drug price negotiations could lead to reimbursement complexities, potential pharmacy closures, and reduced patient access to medications, particularly specialty drugs.
STAT
APRIL 29, 2025
The word came down at 9 a.m. Pacific on April 14 that they were done. Marcia Stefanick of Stanford and three other leaders of regional centers that for decades have researched women’s health heard from their study’s national leaders that their funding would end with the fiscal year. They all had contracts ready and waiting to be signed to extend their parts of the Women’s Health Initiative, a massive, groundbreaking study that has changed medical practice on hormone therapy,
Pharmacy Times
APRIL 30, 2025
Research reveals that children face significant long-term health risks, including kidney, gastrointestinal, and cardiovascular issues, after COVID-19 infection.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PhRMA
APRIL 29, 2025
America’s biopharmaceutical companies are committed to revitalizing American manufacturing, and they continue expanding their U.S. footprint. Supporting nearly five million jobs and more than 1,500 facilities across the U.S., we’re making investments that help develop new treatments and cures and contribute to America’s economy.
Drug Topics
MAY 1, 2025
In the researchers review of data since 1990, they explored the global burden of infertility and the extent in which it is caused by either STIs or maternal sepsis.
STAT
MAY 1, 2025
CVS Health will not sell its Aetna health plans in the Affordable Care Act’s individual marketplaces in 2026, marking the second time in the past decade that Aetna has given up on ACA coverage. CVS expects to lose up to $400 million this year in its ACA plans. The conglomerate set aside $448 million in the first quarter to cover medical claims from ACA members that won’t be covered by insurance premiums.
PharmaVoice
APRIL 28, 2025
After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PhRMA
APRIL 28, 2025
As the United States confronts a resurgence of measles – a disease that was declared eliminated from the United States in 2000 through immunization – it’s a timely reminder of why vaccines remain one of the most powerful tools for preventing dangerous disease, protecting public health and reducing burden on the health care system.
Drug Topics
MAY 1, 2025
A conversation with Sarah Thomas and David Skomo of HealthDyne at Asembias AXS25 Summit.
STAT
APRIL 29, 2025
After 15 years, the Affordable Care Act (ACA) has survived its share of challenges at the Supreme Court. On April 21, I attended the court’s first hearing in the latest of the series of ACA challenges, Kennedy v. Braidwood, which is focused on the ACA’s preventive services coverage requirement. I proudly represented 20 HIV advocacy organizations as amici in the case , urging the court to uphold the law, which requires payer coverage of items and
PharmaVoice
APRIL 30, 2025
A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Hospital Pharmacy Europe
MAY 1, 2025
As the NHS advances, effective clinical leadership in pharmacy is vital to improve the pharmaceutical care of patients. In Scotland, the Scottish Pharmacy Clinical Leadership Fellowship scheme aims to support just that, as Gerry Hughes finds out. The goal of the Scottish Pharmacy Clinical Leadership Fellowship , launched in 2018, is to nurture future pharmacy leaders and advance strategic healthcare goals in Scotland.
Drug Topics
MAY 1, 2025
Douglas Hoey, CEO of NCPA, discusses what pharmacies can do to increase revenue and avoid shutting their doors.
STAT
MAY 1, 2025
As a professor of physiology, I study how scientific evidence gets translated, sometimes clumsily, from the lab to real life. Whether it’s scaling dietary supplements to humans or using biomimicry to mitigate sports concussion , my work often centers on the fine line between meaningful evidence and misleading extrapolation. That’s why I was immediately skeptical when the Food and Drug Administration announced its decision to ban synthetic food dyes like the controversial red dye No
Pharma Marketing Network
APRIL 28, 2025
Introduction Imagine standing at the edge of a revolution, where every tool you need to succeed is finally within reach. That’s precisely where pharmaceutical marketers find themselves today. Pharma marketing innovation is poised for an unprecedented surge in 2025, driven by new technologies, regulatory shifts, and evolving patient expectations.
Hospital Pharmacy Europe
MAY 1, 2025
Consistent adherence to pulmonary hypertension-specific oral therapy significantly improves clinical outcomes, according to a new prospective study evaluating patients with pulmonary arterial hypertension (PAH) and distal chronic thromboembolic pulmonary hypertension (CTEPH). These two conditions are progressive, life-limiting diseases where timely, consistent medication use is critical to stabilise symptoms and prolong survival.
Drug Topics
APRIL 29, 2025
In the first episode of the podcast, Jennifer Goldman and Hailey Choi discuss the latest FDA updates around compounded weight loss medications, clinical concerns and how pharmacists can protect their patients.
STAT
APRIL 28, 2025
For the second consecutive year, the pharmaceutical industry saw its reputation slip among patient advocacy groups, largely due to ongoing concerns over pricing issues, according to a new survey. Of more than 2,500 groups queried, 56% reported the industry had an “excellent” or “good” reputation as it goes about the business of developing and providing medicines.
Pharma Marketing Network
APRIL 27, 2025
Introduction In todays hyper-competitive healthcare space, building a Lead Generation Network in pharma is no longer optionalits essential. Much like a clinical trial needs carefully selected participants, pharma marketers must construct targeted networks to generate high-quality leads. But how does one translate an abstract marketing concept into a practical strategy that complies with strict regulatory frameworks while producing measurable outcomes?
PharmaVoice
MAY 1, 2025
Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding.
Drug Topics
APRIL 30, 2025
Through digital innovations, transparency, and accessibility, pharmacists can help meet patients where they are at to improve their health outcomes.
STAT
MAY 1, 2025
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation. Our choice today is lavender vanilla.
Pharma Marketing Network
APRIL 29, 2025
Introduction Is traditional advertising losing its edge in the pharmaceutical world? As the industry shifts toward data-driven strategies, the power of audience targeting continues to redefine how brands connect with healthcare professionals (HCPs) and patients. While print ads, radio spots, and mass media campaigns once dominated, the ability to reach the right person at the right time through digital channels has quickly taken the lead.
Pharmacy Times
MAY 1, 2025
In clinical trials, the dihydroergotamine (DHE) nasal powder had favorable safety profiles and rapid pain relief in patients with migraine with or without aura.
Drug Topics
MAY 1, 2025
Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.
STAT
APRIL 29, 2025
Gilead Sciences agreed to pay $202 million to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV medicines, the latest example of a controversial practice that has come back to haunt numerous drugmakers over the years. From 2011 through 2017, Gilead held more than 17,300 speaker programs of which 9,500 were dinners to promote sales of HIV drugs that were supposed to be educational.
Expert insights. Personalized for you.
640 
Let's personalize your content